Proactive Investors - Run By Investors For Investors

MaxCyte starts dosing second cohort of patients in early-stage trial of its lead cancer drug

There were no safety concerns from the first set of patients enrolled into the trial, so MaxCyte is to up the dose for those in the second cohort as planned
ovarian cancer
MCY-M11 has been developed from MaxCyte’s own CARMA cell therapy platform

MaxCyte Inc (LON:MXCT) has started dosing the second cohort of patients in the phase I clinical trial of its MCY-M11 cancer immunotherapy.

MCY-M11 is the first drug from MaxCyte’s CARMA cell therapy platform. It is being used to treat 15 women with ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

READ: MaxCyte shows off CARMA platform at Washington DC conference

The women in this second cohort will receive a higher dose of the drug than those who were part of the first wave of patients.

There were no dose-limiting toxicities or safety concerns observed in the first set of cancer sufferers, MaxCyte confirmed.

“Successfully completing patient dosing in our first cohort and initiating dosing in a second higher-dose cohort are important milestones for MaxCyte, representing tangible progress for our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform,” said chief medical officer Claudio Dansky Ullmann.

“We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options.”

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Related Articles

1550850611_CancerHeadline.jpg
February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use